» Articles » PMID: 38008753

The Effects of ARID1A Mutation in Gastric Cancer and Its Significance for Treatment

Overview
Journal Cancer Cell Int
Publisher Biomed Central
Date 2023 Nov 26
PMID 38008753
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer (GC) has emerged as a significant issue in public health all worldwide as a result of its high mortality rate and dismal prognosis. AT-rich interactive domain 1 A (ARID1A) is a vital component of the switch/sucrose-non-fermentable (SWI/SNF) chromatin remodeling complex, and ARID1A mutations occur in various tumors, leading to protein loss and decreased expression; it then affects the tumor biological behavior or prognosis. More significantly, ARID1A mutations will likely be biological markers for immune checkpoint blockade (ICB) treatment and selective targeted therapy. To provide theoretical support for future research on the stratification of individuals with gastric cancer with ARID1A as a biomarker to achieve precision therapy, we have focused on the clinical significance, predictive value, underlying mechanisms, and possible treatment strategies for ARID1A mutations in gastric cancer in this review.

Citing Articles

Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization.

Jaidee R, Jusakul A, Pocasap P, Kukongviriyapan V, Senggunprai L, Prawan A Sci Rep. 2025; 15(1):8621.

PMID: 40074934 PMC: 11904213. DOI: 10.1038/s41598-025-93192-1.


Genomic landscape and potential therapeutic targets in alpha-fetoprotein-producing gastric cancer.

Zan L, Zhang X, Shen L, Zhao Q, Tan D, Peng X Gastric Cancer. 2025; .

PMID: 39928247 DOI: 10.1007/s10120-025-01594-x.


Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology.

Tan W, Nagabhyrava S, Ang-Olson O, Das P, Ladel L, Sailo B Curr Issues Mol Biol. 2024; 46(7):6533-6565.

PMID: 39057032 PMC: 11276574. DOI: 10.3390/cimb46070390.


Genomic events stratifying prognosis of early gastric cancer.

Molinari C, Solaini L, Rebuzzi F, Tedaldi G, Angeli D, Petracci E Gastric Cancer. 2024; 27(6):1189-1200.

PMID: 39028418 PMC: 11513700. DOI: 10.1007/s10120-024-01536-z.


Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic Interpretation.

Angelico G, Attanasio G, Colarossi L, Colarossi C, Montalbano M, Aiello E Cancers (Basel). 2024; 16(11).

PMID: 38893181 PMC: 11171396. DOI: 10.3390/cancers16112062.


References
1.
Dong Z, Wu S, Liao R, Huang S, Wu Y . Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. Tumour Biol. 2016; 37(4):4251-61. DOI: 10.1007/s13277-016-4812-9. View

2.
Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski C, Galle P . Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol. 2012; 69(6):1601-15. DOI: 10.1007/s00280-012-1869-z. View

3.
Giraud J, Bouriez D, Seeneevassen L, Rousseau B, Sifre E, Giese A . Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination. Cancers (Basel). 2019; 11(4). PMC: 6520896. DOI: 10.3390/cancers11040560. View

4.
Wang F, Wei X, Wang F, Xu N, Shen L, Dai G . Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019; 30(9):1479-1486. PMC: 6771223. DOI: 10.1093/annonc/mdz197. View

5.
Luo B, Cheung H, Subramanian A, Sharifnia T, Okamoto M, Yang X . Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008; 105(51):20380-5. PMC: 2629277. DOI: 10.1073/pnas.0810485105. View